ChAdOx1.85A+MVA85A

Vaccine Platform

Viral Vector

Phase of Development

Phase 2a

Candidate Overview

ChAdOx1.85A is a simian adenoviral vector expressing Antigen 85A. MVA85A is a modified vaccinia virus Ankara expressing Antigen 85A.

Sponsor / Lead Developer: University of Oxford

Primary Indication: Prevention of TB disease

Other Indication(s): Prevention of Mtb infection or sustained infection and Prevention of TB recurrence

Target Population(s): Adolescents, Adults, Children, Infants, People cured of active TB, People living with HIV, People with Mtb infection, and People without Mtb infection

Clinical Trials

COMPLETED TRIALS
Registry NumberNCT03681860
Clinical Trial PhasePhase 2a
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Immunogenicity
Target population(s) for clinical trialAdults
Adolescents
_________________________
Registry NumberNCT01829490
Clinical Trial PhasePhase 1
StatusCompleted
Primary endpoint(s) for this clinical trialSafety
Target population(s) for clinical trialAdults